SIR -The pericentromeric region of chromosome 18, specifically 18p11.2, is described as schizophrenia susceptibility locus 1, 2 (the maximum LOD score to date is 3.1 by Schwab et al 1 ), in addition to being a strong candidate region for bipolar disorder. 3 We have previously cloned two novel brain-derived transcripts from this region: the gene for a second human myoinositol monophosphatase (IMPA2) 4 and a gene of unknown function, C18orf1.
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Our prior genetic analysis of IMPA2 generated evidence for its association with Japanese schizophrenia in a case-control context. 6 Owing to an inherent risk for producing false-positive results in case-control designs, we performed a family-based linkage disequilibrium (LD) study as the first step towards identifying relevant genetic loci around 18p11.2, and then followed this up using independent case-control samples. The ethics committee of RIKEN approved the present study, and written informed consent was obtained from all participants.
First, we genotyped 80 independent trios, each composed of schizophrenic offspring (based on DSM-IV) and their parents, using 15 markers that included seven microsatellites and eight single-nucleotide polymorphisms (SNPs) ( Table 1, except for  6409T4C) . These markers, chosen at even intervals as long as possible, were selected from the 14 Mb region spanning 18p11.22 and the proximal q-arm, with the exception of the sparsely represented pericentromeric region and two markers each from the GNAL and IMPA2 genes (the average marker density on 18p is 1/280 kb). This marker spacing is valid for an initial genetic scan, given the recently reported LD distance of 0.5-2 cM retained in the Japanese population. 7 We analyzed genotype data using the extended transmission disequilibrium test (ETDT), 8 which calculates the allele wise TDT statistics that determine the preferential transmission of specific alleles, and the genotype-wise TDT statistic that evaluates the deviation of allele transmission from each parental genotype. We simulated the empirical significance levels of the ETDT results using the MCETDT program, (http://www.mds. qmw.ac.uk/statgen/dcurtis/software.html). P values indicating significantly distorted transmission were obtained from markers D18S852 and D18S40 (Table  1) . Since D18S852 consists of a GCT triplet repeat present within the 3 0 -untranslated region of the C18orf1 gene, we tested another polymorphism, 6409T4C, which we had identified from the same region. 5 This SNP also showed a modest but significant association in both allele-and genotype-wise TDT statistics (Table 1) . However, all three markers lost significance if a Bonferroni correction for multiple testing was applied. To compute the statistical power obtained from the present family-based association study, we used the TDT Power Calculator program. 9 Our sample size had a power of 0.821 to detect significant association, based on a model assuming a dominant trait with an allele frequency of 0.2, a penetrance of 0.4 and a phenocopy risk of 0.4%. 10 In the second stage, to ascertain whether the association of the three markers could be replicated, we analyzed 214 schizophrenics and 313 mentally healthy controls. The samples partially overlapped with those used in the previous study, 6 and are thus regarded as extended samples. None of the markers were significant (P40.05). Since these markers were in LD with each other (Po0.05 by Arlequin at http:// lgb.unige.ch/arlequin/), we compared haplotypic distributions (estimated by Arlequin) that were defined by the combinations of either any two or all three of D18S852, 6409T4C and D18S40, with the aim of increasing statistical power. The analysis revealed that the haplotype constructed from D18S852 and 6409T4C was strongly associated with schizophrenia (nominal P ¼ 0.00001 by CLUMP at http://www.mds. gmw.ac.uk/statgen/dcurtis/software.html; P ¼ 0.00008, corrected for multiple comparisons). The D18S852- 6409T4C D18S40 haplotype was also associated with schizophrenia (P ¼ 0.012), while the 6409T4C-D18S40-(P ¼ 0.274) and D18S852-D18S40 (P ¼ 0.138) were not. The C18orf1 protein is predicted to have a putative type Ib transmembrane domain, a lowdensity lipoprotein receptor class A domain, potential binding sites for src homology 3 and tryptophan tryptophan-domains. It may therefore function by interacting with signaling molecules. 5 From the data presented here, C18orf1 as well as GNAL and IMPA2 on the short arm of chromosome 18 (within a 1.5 Mb region, Table 1 ) show association with schizophrenia or functional psychoses. 1, 6 Recent examples showing fine mapping of complex diseases have demonstrated the significance of clustered positive markers around causal variants frequently interspersed with non significant markers. 11 In this context, the present findings support the idea that the proximal area of 18p is a schizophrenia susceptibility locus, and indicate that the genomic region surrounding the C18orf1 gene warrants further scrutiny. SIR -The pathophysiology of severe depression may be associated with mutual immune and hypothalamic-pituitary-adrenal (HPA) system activation, 1,2 by which infection-induced immune response is triggering the HPA system, thereby changing behavior, 3 and stress hormones, in turn, the immune system. 4 In this context, we investigated infections with two independent agents (Borna disease virus (BDV) and Chlamydia pneumoniae (CP)), one of which already under debate to specifically contribute to depression. [5] [6] [7] [8] Our study provides the first clinical evidence that in depressed patients, infection with Bornavirus is associated with activation of the HPA system.
The study enrolled 48 patients with a major depressive episode (DSM-IV), giving informed consent and presenting with at least 18 points in the Hamilton Depression Scale (HAMD) after a 6-day wash-out, who were kept off psychotropic medication for 1 week (except lorazepam and zolpidem) and subsequently treated with 150 mg amitriptyline or 40 mg paroxetine for weeks 1-4. Excluded were patients with schizophrenia, bipolar or current substance-related disorders. Saliva cortisol was measured daily at 8.00, 16.00 and 22.00 h during weeks À1 to 4, and mean daily concentrations were calculated each week. Citrated blood was drawn weekly for 6 weeks. IgG, IgM and IgA antibodies to CP were analyzed twice (weeks À1 and 4) using a commercially available assay. BDV structural proteins p40 and p24 and specific circulating immune complexes (CICs), together indicating antigenemia as a result of viral replication, were determined by enzyme immune assays (EIAs) using specific monoclonal antibodies. 5, 8 BDV antigen-positive scoring requested moderate or high reactivity in the BDV-CIC and/or plasma antigen EIA. Nonreactivity in either assay was considered BDV negative. Laboratories (endocrinology, microbiology) were mutually kept blind as to their results. Analysis of variance with repeated measures (ANOVA-rm) and t-tests were used to compare HPA system activity between subgroup of patients.
A total of 16 patients were BDV antigen positive at one or more time points, while 17 did not show positive BDV antigen in any of 6-weekly blood samples. In all, 15 subjects were excluded because BDV antigen results did not allow clear stratification. BDV antigen-positive and -negative subgroups did not differ with respect to age (54712 vs 52713 years), pre-treatment, severity (HAMD: 2474 vs 2475) or subtype of depression, antidepressive treatment (seven paroxetine/nine amitriptyline vs nine paroxetine/ eight amitriptyline) or use of lorazepam during the study or HAMD score at day 28 (1579 vs 1176). A higher proportion of women (13/22) than men (3/11) was BDV antigen positive.
Using ANOVA-rm, we found increased baseline cortisol in the BDV antigen positive compared to the negative group (effect of group: F 1,60 ¼ 5.79, Po0.03; effect of time: F 2,60 ¼ 128.24, Po0.0001; 8.00 h:
